Replimune Group, Inc. (REPL) financial statements (2021 and earlier)

Company profile

Business Address 500 UNICORN PARK
WOBURN, MA 01801
State of Incorp. DE
Fiscal Year End March 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
TTM
3/31/2020
3/31/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments493169135
Cash and cash equivalents3246026
Short-term investments169109109
Deferred costs  2
Other undisclosed current assets664
Total current assets:499174141
Noncurrent Assets
Finance lease, right-of-use asset45 
Operating lease, right-of-use asset6 
Property, plant and equipment7712
Restricted cash and investments221
Other undisclosed noncurrent assets 51 
Total noncurrent assets:606013
TOTAL ASSETS:559234154
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities679
Accounts payable237
Accrued liabilities111
Employee-related liabilities322
Debt2  
Other undisclosed current liabilities551
Total current liabilities:131210
Noncurrent Liabilities
Long-term debt and lease obligation30  
Finance lease, liability25 
Operating lease, liability5 
Liabilities, other than long-term debt  0
Deferred rent credit  0
Other undisclosed noncurrent liabilities(5)397
Total noncurrent liabilities:30397
Total liabilities:435016
Stockholders' equity
Stockholders' equity attributable to parent516184138
Common stock000
Additional paid in capital688297199
Accumulated other comprehensive loss(0)(1)(1)
Accumulated deficit(172)(112)(60)
Total stockholders' equity:516184138
TOTAL LIABILITIES AND EQUITY:559234154

Income statement (P&L) ($ in millions)

12/31/2020
TTM
3/31/2020
3/31/2019
Operating expenses(74)(56)(31)
Operating loss:(74)(56)(31)
Nonoperating income (expense)(1)40
Investment income, nonoperating123
Other nonoperating income (expense)(1)(0)0
Interest and debt expense(2)(1) 
Other undisclosed income from continuing operations before equity method investments, income taxes11 
Loss before gain (loss) on sale of properties:(76)(53)(31)
Other undisclosed net income (loss)(0) 62
Net income (loss):(77)(53)31
Other undisclosed net income (loss) attributable to parent1 (62)
Net loss available to common stockholders, diluted:(75)(53)(31)

Comprehensive Income ($ in millions)

12/31/2020
TTM
3/31/2020
3/31/2019
Net income (loss):(77)(53)31
Comprehensive income (loss):(77)(53)31
Other undisclosed comprehensive income (loss), net of tax, attributable to parent20(62)
Comprehensive loss, net of tax, attributable to parent:(74)(53)(32)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: